Back to top
more

Sorrento Therapeutics (SRNE)

(Delayed Data from OTC)

$0.01 USD

0.01
27,471

0.00 (-13.51%)

Updated Jul 12, 2024 03:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Analysts Estimate Sorrento Therapeutics (SRNE) to Report a Decline in Earnings: What to Look Out for

Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Sorrento Therapeutics (SRNE) Stock Options

Investors need to pay close attention to Sorrento Therapeutics (SRNE) stock based on the movements in the options market lately.

Will Sorrento Therapeutics (SRNE) Report Negative Q3 Earnings? What You Should Know

Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for September 8th

AU, INTZ, RIO, SRNE, and PRTH have been added to the Zacks Rank #5 (Strong Sell) List on September 8, 2021

Celsion (CLSN) COVID Vaccine Effective in Pre-Clinical Studies

Celsion (CLSN) announces data from pre-clinical studies for its investigational vaccine platform as a potential treatment for COVID-19.

Sorrento's (SRNE) COVID Vaccine Effective in Pre-Clinical Study

Sorrento (SRNE) announces data from pre-clinical study for its investigational mRNA COVID vaccine. The company also in-licensed rights to highly potent main protease inhibitors against COVID variants.

Sorrento (SRNE) to Report Q2 Earnings: What's in the Cards?

Sorrento (SRNE) will provide updates on earnings and revenues when it releases second-quarter 2021 results.

Will Sorrento Therapeutics (SRNE) Report Negative Q2 Earnings? What You Should Know

Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moving Average Crossover Alert: Sorrento Therapeutics (SRNE)

Sorrento Therapeutics (SRNE) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

New Strong Sell Stocks for March 31st

AROW, BGS, KEX, SRNE, and TOSYY have been added to the Zacks Rank #5 (Strong Sell) List on March 31, 2021

Sorrento Therapeutics (SRNE) Stock Sinks As Market Gains: What You Should Know

Sorrento Therapeutics (SRNE) closed at $10.97 in the latest trading session, marking a -0.32% move from the prior day.

Sorrento Therapeutics (SRNE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sorrento Therapeutics (SRNE) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Sorrento Therapeutics (SRNE) closed at $13.98, marking a -0.71% move from the previous day.

Sorrento (SRNE) to Report Q4 Earnings: What's in the Cards?

Sorrento (SRNE) will provide updates on sales, earnings and pipeline when it reports fourth-quarter 2020 results.

Do Options Traders Know Something About Sorrento (SRNE) Stock We Don't?

Investors need to pay close attention to Sorrento (SRNE) stock based on the movements in the options market lately.

Sorrento Therapeutics (SRNE) Stock Sinks As Market Gains: What You Should Know

Sorrento Therapeutics (SRNE) closed the most recent trading day at $7.03, moving -0.57% from the previous trading session.

Company News for Dec 24, 2020

Companies in the news are: SUPN, PLTR, JAGX, SRNE

Is the Options Market Predicting a Spike in Sorrento Therapeutics (SRNE) Stock?

Investors need to pay close attention to Sorrento Therapeutics (SRNE) stock based on the movements in the options market lately.

Will Sorrento Therapeutics (SRNE) Report Negative Q3 Earnings? What You Should Know

Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sorrento (SRNE) to Report Q3 Earnings: What's in the Cards?

Sorrento (SRNE) will provide updates on earnings and revenues when its releases third-quarter 2020 results.

Sorrento Therapeutics (SRNE) Gains But Lags Market: What You Should Know

In the latest trading session, Sorrento Therapeutics (SRNE) closed at $7.16, marking a +1.13% move from the previous day.

Sorrento Therapeutics (SRNE) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Sorrento Therapeutics (SRNE) closed at $7.92, marking a -1.98% move from the previous day.

Sorrento Therapeutics (SRNE) Outpaces Stock Market Gains: What You Should Know

Sorrento Therapeutics (SRNE) closed the most recent trading day at $11.29, moving +0.98% from the previous trading session.

Sorrento & ViralClear Explore Combination Coronavirus Treatments

Sorrento (SRNE) collaborates with ViralClear Pharmaceuticals to evaluate the combination of antibody and antiviral assets against COVID-19.

Company News for Sep 30, 2020

Companies In The News Are: SRNE, FIT, GOOGL, NIO, BYND, WMT.